1.Acute Acalculous Cholecystitis Associated with Systemic Lupus Erythematosus with Sjogren's Syndrome.
Sung Joon SHIN ; Kyoung Sun NA ; Sung Soo JUNG ; Sang Cheol BAE ; Dae Hyun YOO ; Seong Yoon KIM ; Tae Hwan KIM
The Korean Journal of Internal Medicine 2002;17(1):61-64
Both systemic lupus erythematosus and Sjogren's syndrome are autoimmune diseases. Almost all organs can be involved but the gall bladder is an unusual site. We report a 39-year-old woman with systemic lupus erythematosus and Sjogren's syndrome presenting with acute acalculous cholecystitis. It is a very rare complication and, in the literature review, surgical interventions are mostly applied for treatment. In our case, high dose corticosteroid was tried and clinical manifestations and radiologic findings were improved.
Acute Disease
;
Adult
;
Case Report
;
Cholecystitis/*complications/diagnosis/drug therapy
;
Female
;
Human
;
Lupus Erythematosus, Systemic/*complications/diagnosis
;
Methylprednisolone/therapeutic use
;
Sjogren's Syndrome/*complications/diagnosis
;
Tomography, X-Ray Computed
2.Systemic mononuclear inflammatory vasculopathy associated with Sjogren's syndrome in a patient with primary biliary cirrhosis.
Jun Ki MIN ; Kyung Soo PARK ; Won Jong YU ; Youn Soo LEE ; Sung Min PARK ; Sung Hwan PARK ; Chul Soo CHO ; Ho Youn KIM
The Korean Journal of Internal Medicine 2000;15(1):89-92
We report a 46-year-old woman with primary biliary cirrhosis (PBC) presenting with Sjogren's syndrome and systemic mononuclear inflammatory vasculopathy. Biopsy specimens of sural nerve showed findings consistent with vasculitic neuropathy. Perivascular inflammatory mononuclear cell infiltration was observed on muscle biopsy specimen. The findings of abdominal computed tomography and brain magnetic resonance imaging were suggestive of vasculitis. Clinical manifestations and radiologic findings were improved after high dose prednisolone therapy.
Biopsy, Needle
;
Case Report
;
Diagnosis, Differential
;
Female
;
Follow-Up Studies
;
Human
;
Liver Cirrhosis, Biliary/diagnosis+ACo-
;
Liver Cirrhosis, Biliary/complications+ACo-
;
Middle Age
;
Prednisone/administration +ACY- dosage
;
Sjogren's Syndrome/pathology
;
Sjogren's Syndrome/diagnosis+ACo-
;
Sjogren's Syndrome/complications
;
Sural Nerve/pathology
;
Treatment Outcome
;
Vasculitis/pathology
;
Vasculitis/drug therapy
;
Vasculitis/diagnosis+ACo-
;
Vasculitis/complications
4.Co-development of autoimmune hepatitis and Sjogren's syndrome triggered by the administration of herbal medicines.
Hyo Jeong OH ; Young Mi MOK ; Moon Seong BAEK ; Ji Kyeong LEE ; Bong Soo SEO ; Tae Hyeon KIM ; Keum Ha CHOI ; In Kyeom HWANG ; Ji Eun RA ; Yong Reol OH ; Yong Sung KIM ; Eun Young CHO ; Haak Cheoul KIM ; Young Woo SOHN
Clinical and Molecular Hepatology 2013;19(3):305-308
Autoimmune hepatitis (AIH) has been reported in association with Sjogren's syndrome (SS). Drug-induced AIH has been rarely reported. A rare case of the co-development of AIH and SS in a 53-year-old woman after the consumption of herbal medicines is described. After admission, the patient complained of dryness in her mouth, and she was subsequently diagnosed with SS, which had not been detected previously. The patient's bilirubin and aminotransferase levels initially decreased following conservative management; however, they later began to progressively increase. A diagnosis of AIH was made based on the scoring system proposed by the International Autoimmune Hepatitis Group. The patient was administered a combination of prednisolone and azathioprine, and the results of follow-up liver-function tests were found to be within the normal range. This is an unusual case of AIH and SS triggered simultaneously by the administration of herbal medicines.
Alanine Transaminase/blood
;
Aspartate Aminotransferases/blood
;
Azathioprine/therapeutic use
;
Bilirubin/blood
;
Female
;
Hepatitis, Autoimmune/complications/*diagnosis/drug therapy
;
*Herbal Medicine
;
Humans
;
Liver/pathology
;
Liver Function Tests
;
Middle Aged
;
Prednisolone/therapeutic use
;
Sjogren's Syndrome/complications/*diagnosis/drug therapy
5.A Case of Necrotizing Keratoscleritis in Primary Sjogren's Syndrome.
Won CHOI ; Shin Seok LEE ; Yeong Geol PARK ; Kyung Chul YOON
Korean Journal of Ophthalmology 2011;25(4):275-277
We report on a case of necrotizing keratoscleritis in primary Sjogren's syndrome. A 66-year-old female patient who was complaining of ocular pain, tearing and decreased vision in her right eye for the previous two days was admitted to our hospital. Visual acuity in the right eye was hand movement, and initial examination showed a 3.0 x 1.8 mm uveal mass bulging through a corneoscleral melting site in the nasal region of the right eye. Positive anti-nuclear antibody was identified at a titer of 1:320 with a speckled pattern, and both Sjogren's syndrome A and Sjogren's syndrome B antibody tests were positive, with titers >200 U/mL. A technetium 99m pertechnetate salivary scan revealed chronic sialoadenitis in the submandibular glands. We diagnosed the lesion as necrotizing keratoscleritis due to primary Sjogren's syndrome. A corneoscleral patch graft was performed, followed by immunosuppression including oral cyclosporin and topical prednisolone. During a follow-up period of 12 months, the corneoscleral graft was well maintained with no recurrence.
Aged
;
Diagnosis, Differential
;
Disease Progression
;
Female
;
Follow-Up Studies
;
Glucocorticoids/administration & dosage
;
Humans
;
Keratitis/drug therapy/*etiology/pathology
;
Necrosis
;
Ophthalmic Solutions
;
Scleritis/drug therapy/*etiology/pathology
;
Sjogren's Syndrome/*complications/drug therapy/pathology
;
Visual Acuity
6.Electrolyte Imbalances and Nephrocalcinosis in Acute Phosphate Poisoning on Chronic Type 1 Renal Tubular Acidosis due to Sjogren's Syndrome.
Sung Gun CHO ; Joo Hark YI ; Sang Woong HAN ; Ho Jung KIM
Journal of Korean Medical Science 2013;28(2):336-339
Although renal calcium crystal deposits (nephrocalcinosis) may occur in acute phosphate poisoning as well as type 1 renal tubular acidosis (RTA), hyperphosphatemic hypocalcemia is common in the former while normocalcemic hypokalemia is typical in the latter. Here, as a unique coexistence of these two seperated clinical entities, we report a 30-yr-old woman presenting with carpal spasm related to hypocalcemia (ionized calcium of 1.90 mM/L) due to acute phosphate poisoning after oral sodium phosphate bowel preparation, which resolved rapidly after calcium gluconate intravenously. Subsequently, type 1 RTA due to Sjogren's syndrome was unveiled by sustained hypokalemia (3.3 to 3.4 mEq/L), persistent alkaline urine pH (> 6.0) despite metabolic acidosis, and medullary nephrocalcinosis. Through this case report, the differential points of nephrocalcinosis and electrolyte imbalances between them are discussed, and focused more on diagnostic tests and managements of type 1 RTA.
Acidosis, Renal Tubular/*diagnosis/etiology
;
Acute Disease
;
Adult
;
Antibodies, Antinuclear/blood
;
Calcium Gluconate/therapeutic use
;
Chronic Disease
;
Female
;
Humans
;
Hydrogen-Ion Concentration
;
Hypocalcemia/*chemically induced/complications/drug therapy
;
Nephrocalcinosis/complications/*diagnosis/ultrasonography
;
Parotid Gland/ultrasonography
;
Phosphates/*adverse effects
;
Salivary Glands/radionuclide imaging
;
Sjogren's Syndrome/complications/*diagnosis/metabolism
;
Submandibular Gland/ultrasonography
7.Effect of Hydroxychloroquine Treatment on Dry Eyes in Subjects with Primary Sjögren's Syndrome: a Double-Blind Randomized Control Study.
Chang Ho YOON ; Hyun Ju LEE ; Eun Young LEE ; Eun Bong LEE ; Won Woo LEE ; Mee Kum KIM ; Won Ryang WEE
Journal of Korean Medical Science 2016;31(7):1127-1135
The effect of hydroxychloroquine (HCQ) on dry eye has not been fully determined. This study aimed to compare the 12-week efficacy of HCQ medication with that of a placebo in the management of dry eye in primary Sjögren's syndrome (pSS). A double-blind, randomized control study was conducted in 39 pSS subjects from May 2011 through August 2013. pSS was diagnosed based on the classification criteria of the American-European Consensus Group. Subjects received 300 mg of HCQ or placebo once daily for 12 weeks and were evaluated at baseline, 6, and 12 weeks, with a re-visit at 16 weeks after drug discontinuance. The fluorescein staining score, Schirmer test score, tear film break-up time (TBUT), and ocular surface disease index (OSDI) were measured, and tears and blood were collected for ESR, IL-6, IL-17, B-cell activating factor (BAFF), and Th17 cell analysis. Color testing was performed and the fundus was examined to monitor HCQ complications. Twenty-six subjects completed the follow-up. The fluorescein staining score and Schirmer test score did not differ significantly. The OSDI improved with medication in the HCQ group but was not significantly different between the groups. TBUT, serum IL-6, ESR, serum and tear BAFF, and the proportion of Th17 cells did not change in either group. HCQ at 300 mg daily for 12 weeks has no apparent clinical benefit for dry eye and systemic inflammation in pSS (ClinicalTrials.gov. NCT01601028).
Aged
;
B-Cell Activating Factor/analysis/blood
;
Blood Sedimentation
;
Double-Blind Method
;
Drug Administration Schedule
;
Dry Eye Syndromes/complications/*drug therapy
;
Enzyme-Linked Immunosorbent Assay
;
Female
;
Humans
;
Hydroxychloroquine/*therapeutic use
;
Interleukin-16/analysis/blood
;
Interleukin-17/analysis/blood
;
Male
;
Middle Aged
;
Placebo Effect
;
Prospective Studies
;
Sjogren's Syndrome/*complications/diagnosis
;
Th17 Cells/cytology/immunology
;
Treatment Outcome